Country: Malta
Language: English
Source: Medicines Authority
DYDROGESTERONE; ESTRADIOL
Mylan Products Limited
G03FA14
DYDROGESTERONE; ESTRADIOL
FILM-COATED TABLET
DYDROGESTERONE 5 mg; ESTRADIOL 1 mg
POM
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Authorised
pharma code pharma code PACKAGE LEAFLET: INFORMATION FOR THE USER Femoston ® -conti 1mg/ 5mg film-coated tablets Active substances: estradiol/dydrogesterone Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. The full name of your medicine is Femoston-conti 1mg/ 5mg. In this leaflet the shorter name Femoston- conti is used. What is in this leaflet: 1. What Femoston-conti is and what it is used for 2. What you need to know before you take Femoston- conti 3. How to take Femoston-conti 4. Possible side effects 5. How to store Femoston-conti 6. Contents of the pack and other information 1. What Femoston-conti is and what it is used for. Femoston-conti is a Hormone Replacement Therapy (HRT). It contains two types of female hormones, an oestrogen called estradiol and a progestogen called dydrogesterone. Femoston-conti is used in postmenopausal women with at least 12 months since their last natural period. Femoston-conti is used for Relief of symptoms occurring after menopause During the menopause, the amount of the oestrogen produced by a woman’s body drops. This can cause symptoms such as hot face, neck and chest (“hot flushes”). Femoston-conti alleviates these symptoms after menopause. You will only be prescribed Femoston- conti if your symptoms seriously hinder your daily life. Prevention of osteoporosis After the menopause some women may develop fragile bones (osteoporosis). You should discuss all available options with your doctor. If you are at an increased risk of fractures due to osteoporosis and other medicines are not s Read the complete document
Page 1 of 18 SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) FEMOSTON-CONTI 1MG/ 5MG FILM-COATED TABLETS 1. NAME OF THE MEDICINAL PRODUCT Femoston-conti 1mg/ 5mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 28 tablets, each containing 1 mg 17β-estradiol (as hemihydrate) and 5 mg dydrogesterone. Excipient with known effect: lactose monohydrate 114.7 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Round, biconvex tablets marked 379 on one side (7mm) Salmon coloured 1/5 mg tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 12 months since last menses. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also section 4.4) The experience in treating women older than 65 years is limited. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Femoston-conti 1mg/ 5mg film-coated tablets are a continuous combined HRT for oral use. The oestrogen and the progestogen are given every day without interruption. The dosage is one tablet per day for a 28 day cycle. Page 2 of 18 SUMMARY OF PRODUCT CHARACTERISTICS (SMPC) FEMOSTON-CONTI 1MG/ 5MG FILM-COATED TABLETS Femoston-conti 1mg/ 5mg film-coated tablets should be taken continuously without a break between packs. For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used. Continuous combined treatment may be started with Femoston-conti 1mg/ 5mg film-coated tablets depending on the time since menopause and severity of symptoms. Women experiencing a natural menopause should commence treatment with Femoston-conti 1mg/ 5mg film-coated tablets 12 months after their last natural menstrual bleed. For surgically induced menopause, treatment may start immediately. Depending on t Read the complete document